Company intelligence / Profile preview

Excyte Biopharma Ltd

Beijing, Beijing, China

Ownership: Private
Development stage: Phase 1

Overview

YK012 (CD19 x CD3) is in Phase 2 for CD19-positive B-cell acute lymphoblastic leukemia. YKST02 (BCMA x CD3) is in Phase 1 for Multiple Myeloma, with partial response observed at 3mg dose with no adverse reactions at doses of 6mg or lower. Several other candidates are in preclinical development.[2][5][6][9]

Therapeutic areas: OncologyNephrology
Modalities: Bispecific antibodiesMonoclonal antibodiesTrispecific antibodiesBispecific T-cell Engagers (BiTE)CAR-T/TCR-T cell immunotherapy
Industry: Biotech

Drug pipeline

11 assets

YK012

10 more assets in the full pipeline.

Request access →

Partnerships

Beijing Highthink Pharmaceutical Technology Service Co., Ltd.Affiliated Beijing Chaoyang Hospital of Capital Medical University

Beyond the preview

Go deeper on Excyte Biopharma Ltd.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Excyte Biopharma Ltd.

Explore the full profile